


IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Original): A 1-N-aminobenzoimidazole derivative represented by the following formula (I):



wherein:

R¹ represents an alkyl group optionally substituted by one or more substituents which may be the same or different and which are selected from halogen atoms, hydroxy groups, phenyl groups, hydroxyphenyl groups, amino groups, alkoxy groups, alkoxycarbonyl groups or alkylamino groups, an alkenyl group, an acyl group, an alkoxycarbonyl group, a benzyloxycarbonyl group, a formyl group, a phenyl group, or a hydrogen atom;

R² represents an alkyl group which may be substituted by a hydroxy or alkoxycarbonyl group, an acyl group which may be substituted by a halogen atom, a cyano group, a carboxyl group, an alkoxycarbonyl group, or a hydrogen atom;

R³, R⁵ and R⁶ may be the same or different and each represents an alkyl group, an alkoxy group or a hydrogen atom;

R⁴ represents an alkyl group optionally substituted by one or more substituents which may be the same or different and which are selected from halogen atoms, hydroxy groups, alkyl groups which may be substituted by 1 to 8 halogen atoms, alkoxy groups which may be substituted by 1 to 8 halogen atoms, furyl groups or morpholino groups, or a geranyl group;

A represents a benzene ring, a pyridine ring, or a thiophene ring;

B represents an oxygen atom or a sulfur atom; and

n stands for an integer of from 0 to 2; or a salt thereof.

Claim 2 (Original): The 1-N-aminobenzimidazole derivative or a salt thereof according to claim 1, wherein in said formula (I),

R¹ is a C₁₋₆ alkyl group optionally substituted by 1 or more substituents which may be the same or different and which are selected from halogen atoms, hydroxy groups, phenyl groups, hydroxyphenyl groups, amino groups, C₁₋₆ alkoxy groups, C₁₋₆ alkoxycarbonyl groups or C₁₋₆ alkoxyamino groups, a C₂₋₆ alkenyl group, a C₂₋₆ acyl group, a C₁₋₆ alkoxycarbonyl group, a benzyloxycarbonyl group, a formyl group, a phenyl group, or a hydrogen atom;

R² is a C₁₋₆ alkyl group which may be substituted by a hydroxyl group or a C₁₋₆ alkoxycarbonyl group, a C₂₋₆ acyl group which may be substituted by a halogen atom, a cyano group, a carboxyl group, a C₁₋₆ alkoxycarbonyl group, or a hydrogen atom;

R³, R⁵ and R⁶ may be the same or different and are each a C₁₋₆ alkyl group, a C₁₋₆ alkoxy group or a hydrogen atom;

R⁴ is a C₁₋₆ alkyl group optionally substituted by one or more substituents which may be the same or different and which are selected from halogen atoms, hydroxy groups, C₁₋₆ alkyl groups which may be substituted by 1 to 8 halogen atoms, C₁₋₆ alkoxy groups which may be substituted by 1 to 8 halogen atoms, furyl groups or morpholino groups, or a geranyl group;

A represents a benzene ring, a pyridine ring, or a thiophene ring;

B represents an oxygen atom or a sulfur atom; and

n stands for an integer of from 0 to 2.

Claim 3 (Original): The 1-N-aminobenzimidazole derivative or a salt thereof according to claim 1, wherein in said formula (I),

R¹ is an unsubstituted C₁₋₆ alkyl group, a C₁₋₆ alkyl group substituted by three halogen atoms, a C₁₋₆ alkyl group substituted by one hydroxy, phenyl or hydroxyphenyl group, a C₁₋₆ alkyl group substituted by one C₁₋₆ alkoxy carbonyl group, a C₁₋₆ alkyl group substituted by one di-(C₁₋₆ alkyl)amino group, a C₂₋₆ alkenyl group, an allyl group, or a phenyl group;

R² is a C₁₋₆ alkyl group substituted by one hydroxy or C₁₋₆ alkoxy carbonyl group, a C₂₋₆ acyl group substituted by two halogen atoms, a cyano group, a carboxyl group, a C₁₋₆ alkoxy carbonyl group, or a hydrogen atom;

R³, R⁵ and R⁶ may be the same or different and are each a C₁₋₆ alkyl group, a C₁₋₆ alkoxy group or a hydrogen atom;

R⁴ is a C₁₋₆ alkyl group optionally substituted by one or more substituents which may be the same or different and which are selected from halogen atoms, hydroxy groups, C₁₋₆ alkyl groups which may be substituted by 1 to 8 halogen atoms, C₁₋₆ alkoxy groups which may be substituted by 1 to 8 halogen atoms, furyl groups or morpholino groups, or a geranyl group;

A represents a benzene ring;

B represents an oxygen atom; and

n is 1.

Claim 4 (Original): The 1-N-aminobenzimidazole derivative or a salt thereof according to claim 1, wherein in said formula (I),

R¹ is a methyl, ethyl, propyl, isopropyl, isobutyl, hexyl, 2-hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 4-hydroxybutyl, 5-hydroxypentyl, 2,2,2,-trifluoroethyl, 2-

phenethyl, benzyl, allyl, p-hydroxybenzyl, 2-hydroxy-2-phenethyl, 2-dimethylaminoethyl, methoxycarbonylmethyl or phenyl group;

R² is a methoxy, difluoromethoxy, cyano, methoxycarbonyl, methoxycarbonylmethyl, carboxyl or hydroxymethyl group, or a hydrogen atom;

R³ is a methyl or methoxy group, or a hydrogen atom;

R⁴ is a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, hexyl, octyl, 2-methoxyethyl, 3-methoxypropyl, 2,2,2-trifluoroethyl, 4,4,4-trifluorobutyl, 2,2,3,3,4,4,4-heptafluorobutyl, 2-(2,2,2-trifluoroethoxy)ethyl, 3-(2,2,2-trifluoroethoxy)propyl, 2-hydroxyethyl or geranyl group;

R⁵ is a methyl group or a hydrogen atom;

R⁶ is a hydrogen atom;

A is a benzene ring;

B is an oxygen atom; and

n is 1.

Claim 5 (Currently Amended): ~~The~~ A medicine comprising ~~[[a]]~~ the compound according to ~~any one of claims 1-4~~ or a salt thereof as claimed in claim 1.

Claim 6 (Currently Amended): The medicine according to claim 5, ~~which~~ wherein the medicine is a peptic ulcer therapeutic agent.

Claim 7 (Currently Amended): A medicinal composition comprising ~~[[a]]~~ the compound according to ~~any one of claims 1-4~~ claim 1 and a pharmacologically acceptable carrier.

Claim 8 (Currently Amended): ~~Use of~~ A method for the production of a medicine comprising:

incorporating into a pharmaceutically acceptable carrier a compound according to claim 1.

~~any one of claims 1-4 for the production of a medicine.~~

Claim 9 (Currently Amended): ~~Use~~ A method for the production of a medicine according to claim 8, wherein said medicine is a peptic ulcer therapeutic agent.

Claim 10 (Currently Amended): A method for the treatment of a peptic ulcer, which comprises administering an effective amount of [[a]] the compound according to ~~any one of claims 1-4~~ claim 1 to a patient in need thereof.

Claim 11 (New): A method for the treatment of a peptic ulcer, which comprises administering an effective amount of the medicine of claim 5 to a patient in need thereof.

Claim 12 (New): A method for the treatment of a peptic ulcer, which comprises administering an effective amount of the medicine of claim 7 to a patient in need thereof.

SUPPORT FOR THE AMENDMENT

Claims 1-10 remain active in this application. Claims 1-4 are original claims and 5-10 are presently amended. Claims 11-12 are added.

Support for these amendments is found at page 3, line 25, page 20, line 4 and throughout the originally filed specification and claims. No new matter is believed to have been added.

Applicants submit this application is now in condition for examination on the merits and early notification of such action is earnestly solicited.